Soru

Zorluk: OrtaReproductive Endocrinology and Infertility

An infertility evaluation is initiated for a couple who have been unable to achieve a pregnancy despite having regular, unprotected intercourse for the past 1818 months. The female partner is 2727 years of age. She reports that since discontinuing oral contraceptive pills a year and a half ago, she has not experienced a single menstrual period. Prior to starting oral contraceptives at age 1818, her menstrual cycles occurred irregularly every 33 to 55 months. She competes in triathlons and maintains a strict vegan diet. Her body mass index is 17.5 kg/m217.5 \text{ kg/m}^2. Vital signs show a blood pressure of 90/60 mmHg90/60 \text{ mmHg} and a pulse of 50/min50/min. Physical examination reveals Tanner stage V breast development and normal pubic hair, with no hirsutism, acne, or thyromegaly. Pelvic ultrasound demonstrates a normal-appearing uterus with a thin endometrial stripe (3 mm3 \text{ mm}) and small, bilateral ovaries without cysts. Laboratory evaluation shows:

TestResult
β\beta-hCGNegative
Follicle-stimulating hormone2.0 mIU/mL2.0 \text{ mIU/mL}
Luteinizing hormone1.1 mIU/mL1.1 \text{ mIU/mL}
Estradiol15 pg/mL15 \text{ pg/mL}
Thyroid-stimulating hormone1.8 \muU/mL1.8 \text{ \mu U/mL}
Prolactin8 ng/mL8 \text{ ng/mL}

After 66 months of concerted efforts at nutritional rehabilitation and exercise reduction, her body mass index remains 17.8 kg/m217.8 \text{ kg/m}^2 and her amenorrhea persists. Which of the following is the most appropriate next step in medical management to help this patient conceive?

  1. Exogenous gonadotropin therapyCevap
  2. B
    Letrozole therapy
  3. C
    Clomiphene citrate therapy
  4. D
    Cabergoline administration
  5. E
    Levothyroxine supplementation

Cevap

Exogenous gonadotropin therapy
This patient's clinical presentation—secondary amenorrhea in the setting of intense athletic training, low body weight, low estradiol, and inappropriately low-normal gonadotropins—is diagnostic of functional hypothalamic amenorrhea (FHA). FHA is a form of hypogonadotropic hypogonadism caused by a relative energy deficit that suppresses pulsatile gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus. The first-line management for FHA is lifestyle modification (e.g., increased caloric intake, decreased exercise). When these modifications fail and the patient desires pregnancy, ovulation induction is required. Because the hypothalamic-pituitary axis is functionally dormant, medications that act by modulating estrogen feedback (such as aromatase inhibitors or selective estrogen receptor modulators) are generally ineffective. Instead, the ovaries must be stimulated directly using exogenous gonadotropins (recombinant FSH and LH) or, if available, pulsatile GnRH therapy.

Adım Adım Çözüm

1
Identify the primary diagnosis based on the clinical presentation.
The patient has functional hypothalamic amenorrhea.
She is a highly active, low-BMI athlete presenting with secondary amenorrhea, profound hypoestrogenism (thin endometrium, low estradiol), and inappropriately low-normal gonadotropins (FSH, LH).
2
Determine the outcome of conservative management.
Lifestyle modifications were unsuccessful.
Despite 6 months of attempted nutritional rehabilitation, her BMI remains low and she remains anovulatory.
3
Select the appropriate pharmacologic intervention for this specific etiology of anovulation.
Exogenous gonadotropins are required.
Because her hypothalamus is failing to secrete adequate GnRH, medications that rely on altering endogenous feedback mechanisms (like letrozole or clomiphene) will fail. Direct ovarian stimulation with exogenous FSH/LH is necessary.

Anahtar Kavram

In patients with functional hypothalamic amenorrhea who do not respond to lifestyle modifications, exogenous gonadotropins or pulsatile GnRH therapy is required for ovulation induction because medications like letrozole and clomiphene citrate rely on an intact hypothalamic-pituitary-ovarian axis.
Tahmini Süre:1m 30s
Bu soruyu puanla